Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Research in animals and humans has associated Alzheimer's disease (AD) with decreased cerebrospinal fluid levels of insulin in combination with decreased insulin sensitivity (insulin resistance) in the brain. This phenomenon is accompanied by attenuated receptor expression of insulin and insulin-like growth factor, enhanced serine phosphorylation of insulin receptor substrate-1, and impaired transport of insulin across the blood-brain barrier. Moreover, clinical trials have demonstrated that intranasal insulin improves both memory performance and metabolic integrity of the brain in patients suffering from AD or its prodrome, mild cognitive impairment. These results, in conjunction with the finding that insulin mitigates hippocampal synapse vulnerability to beta amyloid, a peptide thought to be causative in the development of AD, provide a strong rationale for hypothesizing that pharmacological strategies bolstering brain insulin signaling, such as intranasal administration of insulin, could have significant potential in the treatment and prevention of AD. With this view in mind, the review at hand will present molecular mechanisms potentially underlying the memory-enhancing and neuroprotective effects of intranasal insulin. Then, we will discuss the results of intranasal insulin studies that have demonstrated that enhancing brain insulin signaling improves memory and learning processes in both cognitively healthy and impaired humans. Finally, we will provide an overview of neuroimaging studies indicating that disturbances in insulin metabolism--such as insulin resistance in obesity, type 2 diabetes and AD--and altered brain responses to insulin are linked to decreased cerebral volume and especially to hippocampal atrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
- Retracted
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationGlobal prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359 · cited 1×
“AD brains further display elevated levels of phosphorylated JNK [39], which is known to counteract peripheral insulin signaling [39, 68].”
BackgroundTalbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 10×
“In line with this hypothesis, AD patients show reduced brain insulin receptor sensitivity [9, 10], hypophosphorylation of the insulin receptor and downstream second messengers such as the insulin receptor substrate-1 [10, 11] and attenuated insulin and insulin-like growth factor receptor expression [11].”
BackgroundResultInfluentialSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366 · cited 1×
“with MCI and AD [42, 43] and that diabetes is a risk factor for AD [44], screening for insulin resistance may provide a relatively low-cost, non-invasive means for identifying adults at risk to develop the disease.”
BackgroundSniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Self-citation
Cited by
Kellar, D., & Craft, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30231-3 · Cited by 832
Self-citationMechanism of intranasal drug delivery directly to the brain
Crowe, T. P., Greenlee, M. H. W., Kanthasamy, A. G., & Hsu, W. H. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.12.025 · Cited by 721
De Felice, F. G., & Ferreira, S. T. (2014) · Diabetes · doi:10.2337/db13-1954 · Cited by 639
Self-citationIs Alzheimer’s disease a type 3 diabetes? A critical appraisal
Kandimalla, R., Thirumala, V., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.018 · Cited by 621
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans
Kullmann, S., Heni, M., Hallschmid, M., Fritsche, A., Preissl, H., & Häring, H.-U. (2016) · Physiological Reviews · doi:10.1152/physrev.00032.2015 · Cited by 622
Self-citationGejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449
Santos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
Butterfield, D. A., Di Domenico, F., & Barone, E. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.010 · Cited by 402
13. Older Adults: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s013 · Cited by 381
How does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Hippocampal Insulin Resistance Impairs Spatial Learning and Synaptic Plasticity
Grillo, C. A., Piroli, G. G., Lawrence, R. C., Wrighten, S. A., Green, A. J., Wilson, S. P., Sakai, R. R., Kelly, S. J., Wilson, M. A., Mott, D. D., et al. (2015) · Diabetes · doi:10.2337/db15-0596 · Cited by 308
Djupesland, P. G., Messina, J. C., & Mahmoud, R. A. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.41 · Cited by 295
Aberrant insulin signaling in Alzheimer's disease: current knowledge
Bedse, G., Di Domenico, F., Serviddio, G., & Cassano, T. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00204 · Cited by 292
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 288
Self-citationAdvances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285
Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages
Neth, B. J., & Craft, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00345 · Cited by 272
Self-citationCurrent Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270
“In theory, insulin delivery directly to the brain will activate cerebral insulin signaling leading to improvements in memory processing and will result in neuroprotection [124, 125].”
BackgroundInsulin Resistance and Oxidative Stress in the Brain: What’s New?
Maciejczyk, M., Żebrowska, E., & Chabowski, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040874 · Cited by 262
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Self-citationImpaired insulin action in the human brain: causes and metabolic consequences
Heni, M., Kullmann, S., Preissl, H., Fritsche, A., & Häring, H.-U. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.173 · Cited by 245
Insulin Regulates Brain Function, but How Does It Get There?
Gray, S. M., Meijer, R. I., & Barrett, E. J. (2014) · Diabetes · doi:10.2337/db14-0340 · Cited by 206
“Beyond the CNS effects of insulin on nutrient intake and acute metabolic effects, there is tantalizing emerging data on the effects of insulin on memory and cognition (19,20).”
BackgroundBrain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180
Self-citationZhang, H., Hao, Y., Manor, B., Novak, P., Milberg, W., Zhang, J., Fang, J., & Novak, V. (2015) · Diabetes · doi:10.2337/db14-1000 · Cited by 176
“Brain insulin plays an important role as a neuromodulator in cognition (4,5), energy homeostasis, food intake, sympathetic activity, neuron-astrocyte signaling, synapse formation, and neuronal survival (7,30).”
BackgroundZhang, L., Zhang, L., Li, L., & Hölscher, C. (2019) · Journal of Parkinson's Disease · doi:10.3233/jpd-181503 · Cited by 173
Self-citationMcClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170
Self-citationSharma, M. K., Jalewa, J., & Hölscher, C. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12469 · Cited by 151
Self-citationDistribution of insulin in trigeminal nerve and brain after intranasal administration
Lochhead, J. J., Kellohen, K. L., Ronaldson, P. T., & Davis, T. P. (2019) · Scientific Reports · doi:10.1038/s41598-019-39191-5 · Cited by 146
Chakrabarti, S., Kumar Khemka, V., Banerjee, A., Chatterjee, G., Ganguly, A., & Biswas, A. (2015) · Aging and disease · doi:10.14336/ad.2014.002 · Cited by 134
Huang, M., Hu, M., Song, Q., Song, H., Huang, J., Gu, X., Wang, X., Chen, J., Kang, T., Feng, X., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b03124 · Cited by 127
Agostinone, J., Alarcon-Martinez, L., Gamlin, C., Yu, W.-Q., Wong, R. O. L., & Di Polo, A. (2018) · Brain · doi:10.1093/brain/awy142 · Cited by 124
Glucose metabolism and AD: evidence for a potential diabetes type 3
González, A., Calfío, C., Churruca, M., & Maccioni, R. B. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00996-8 · Cited by 112
Safety of intranasal human insulin: A review
Schmid, V., Kullmann, S., Gfrörer, W., Hund, V., Hallschmid, M., Lipp, H., Häring, H., Preissl, H., Fritsche, A., & Heni, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13279 · Cited by 110
Self-citationBanik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150136 · Cited by 102
Wu, H., Zhou, Y., Wang, Y., Tong, L., Wang, F., Song, S., Xu, L., Liu, B., Yan, H., & Sun, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.717192 · Cited by 90
Stern, S. A., Chen, D. Y., & Alberini, C. M. (2014) · Learning & Memory · doi:10.1101/lm.029348.112 · Cited by 89
Liu, P., Wang, Z.-H., Kang, S. S., Liu, X., Xia, Y., Chan, C.-B., & Ye, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01600-z · Cited by 77
“T2DM patients display increased risk of developing mild cognitive impairment (MCI), dementia, or AD, and AD patients show progressive brain insulin resistance and insulin deficiency.”
BackgroundCentral Insulin Administration Improves Odor-Cued Reactivation of Spatial Memory in Young Men
Brünner, Y. F., Kofoet, A., Benedict, C., & Freiherr, J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3018 · Cited by 68
“Given that intranasal insulin can boost memory formation in cognitively impaired humans (13, 15, 16, 18, 24, 43), by possibly restoring CNS insulin levels, provides further support for the hypothesis that intranasal insulin may be a promising option to slow the development or progress of AD.”
BackgroundSelf-citationGross, C., & Bassell, G. J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00012 · Cited by 63
Ferreira, S. T. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12959 · Cited by 59
Salameh, T. S., Rhea, E. M., Banks, W. A., & Hanson, A. J. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216660770 · Cited by 51
“CNS insulin action is impaired in people with AD, and chronic peripheral hyperinsulinemia serves to reduce transport of insulin into the brain.(38,39) There have been many post-mortem brain studies showing decreases in key insulin signaling proteins in the brains of people with AD.”
BackgroundZolochevska, O., & Taglialatela, G. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160518142110 · Cited by 49
“Insulin prevents binding of Aβ oligomers to the synapse thus improving cognitive performance in patients with early AD [52, 53].”
BackgroundZhang, Y., Yin, F., Liu, J., Liu, Z., Guo, L., Xia, Z., & Zidichouski, J. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.04.002 · Cited by 45
Kazemeini, S., Nadeem-Tariq, A., Shih, R., Rafanan, J., Ghani, N., & Vida, T. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111720 · Cited by 41
“Studies have demonstrated that insulin administration through intranasal and intracere-broventricular routes can enhance spatial memory, regulate hippocampal activity, and partially restore cognitive function in AD patients [203].”
BackgroundLi, L., Zhang, L.-Y., Jin, Q.-Q., & Hölscher, C. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.303045 · Cited by 38
Self-citationTian, S., Tan, S., Jia, W., Zhao, J., & Sun, X. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15277 · Cited by 20
Santiago, J. C. P., & Hallschmid, M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00054 · Cited by 18
“…in central nervous insulin sensitivity have been linked to cognitive deficits and Alzheimer’s disease, pathologies associated with advanced age (Freiherr et al., 2013), our results suggest that, at least in healthy individuals, age does not independently affect the role of insulin in central…”
BackgroundSelf-citationBrünner, Y. F., Rodriguez-Raecke, R., Mutic, S., Benedict, C., & Freiherr, J. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.07.027 · Cited by 17
Self-citationIdentification and Experimental Validation of Marker Genes between Diabetes and Alzheimer’s Disease
Huang, C., Wen, X., Xie, H., Hu, D., & Li, K. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8122532 · Cited by 15
Metadata
- Authors
- Freiherr, J., Hallschmid, M., Frey, W. H., Brünner, Y. F., Chapman, C. D., Hölscher, C., Craft, S., De Felice, F. G., & Benedict, C.
- Venue
- CNS Drugs
- Published
- 2013-05-30
- Volume
- 27
- Issue
- 7
- Pages
- 505-514
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2043381283
- Cited by
- 468
- References
- 94
- FWCI
- 32.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.